Sangamo Therapeutics, Inc. is experiencing a downturn today, with discussions on Reddit highlighting concerns over potential legal actions. A Reddit user pointed out that law firms are targeting Sangamo following Pfizer's decision to discontinue its collaboration on the HemA gene therapy. This has led to speculation about possible Rule 10(b) violations, which are often pursued by a small number of law firms
Sangamo Therapeutics (SGMO) experienced a decline today, closing at $1.17, down 4.12% from the previous close of $1.22. The stock opened at $1.24, reached a high of $1.25, and dipped to a low of $1.12, with trading volume at 5,137,887 shares, about 49.43% of its average. The decline follows broader negative sentiment in the gene editing sector, influenced by Intellia Therapeutics' announcement of a 27% staf
There is no specific news today explaining the decline in Sangamo Therapeutics, Inc.'s stock price. However, the recent developments regarding the company's hemophilia A gene therapy program could still be influencing investor sentiment. On December 30, 2024, Sangamo announced it would regain full rights to the program after Pfizer decided to cease its development. This has led to speculation about Sangamo'
Sangamo Therapeutics, Inc. (SGMO) is experiencing a notable increase in its stock price today, likely driven by ongoing investor interest following the recent announcement that the company will regain full rights to its hemophilia A gene therapy program. This development comes after Pfizer's decision to cease development of giroctocogene fitelparvovec, which was disclosed on December 30, 2024. The return of
Sangamo Therapeutics, Inc. (SGMO) is experiencing a notable increase in its stock price today, likely driven by the ongoing investor interest following the recent announcement that the company will regain full rights to its hemophilia A gene therapy program, giroctocogene fitelparvovec. This development comes after Pfizer's decision to cease its involvement in the program, which was disclosed on January 6th
Sangamo Therapeutics (SGMO) saw its stock price rise by 3.85% to close at $1.35 on January 6th, after opening at the same price. The stock reached an intraday high of $1.45 before settling back. The increase in price was primarily driven by the announcement that Sangamo will regain full rights to its hemophilia A gene therapy program, giroctocogene fitelparvovec, following Pfizer's decision to cease its dev
Sangamo Therapeutics, Inc. is seeing an uptick in its stock price today, likely driven by the recent announcement that the company will regain full rights to its hemophilia A gene therapy program. This follows Pfizer's decision to cease development of giroctocogene fitelparvovec, a move that was disclosed early on January 6th. The return of full rights to this program has sparked investor speculation about
Sangamo Therapeutics, Inc. (SGMO) is experiencing a notable rise in its stock price today, likely driven by increased investor interest following recent developments. A key factor contributing to this surge is the announcement of a licensing agreement with Astellas Pharma, allowing the use of Sangamo's neurotropic adeno-associated virus capsid, STAC-BBB. This agreement may have bolstered investor confidence
Sangamo Therapeutics, Inc. (SGMO) is experiencing a notable rise in its stock price today, likely driven by a recent "buy" rating reaffirmed by HC Wainwright, which set a $10.00 price objective on the shares. This positive analyst sentiment may be bolstering investor confidence, especially following the company's recent challenges, including the termination of its collaboration with Pfizer. Additionally, th
Sangamo Therapeutics, Inc. (SGMO) is experiencing a rise in its stock price today, likely due to ongoing investor interest following recent developments. Despite the termination of its collaboration with Pfizer on the hemophilia A gene therapy, giroctocogene fitelparvovec, Sangamo has regained full rights to the program. This move has sparked speculation about the company's next steps, with investors hopefu
Sangamo Therapeutics (SGMO) saw a notable increase in its stock price on January 2nd, closing at $1.13, up 10.78% from the previous close of $1.02. The stock opened at $1.02 and reached a high of $1.14 during the trading session, with a significant trading volume of 13,438,390 shares, which is 140.53% of its average volume. The price movement comes in the wake of recent developments regarding Sangamo's col
Sangamo Therapeutics is facing a challenging start to the year as its stock continues to decline following Pfizer's decision to terminate their collaboration on the hemophilia A gene therapy, giroctocogene fitelparvovec. Despite positive Phase III trial results, Pfizer has opted not to proceed with regulatory submissions, leaving Sangamo to regain full rights to the program. This move has deprived Sangamo o
Sangamo Therapeutics is experiencing a significant drop in its stock price following Pfizer's decision to terminate their collaboration on the development of giroctocogene fitelparvovec, a gene therapy candidate for hemophilia A. This unexpected move by Pfizer, despite positive phase III results, has led Sangamo to regain full rights to the therapy. The company is now exploring options to continue the progr
Sangamo Therapeutics, Inc. is experiencing a significant drop in its stock price following Pfizer's decision to terminate their collaboration on the development of giroctocogene fitelparvovec, a gene therapy program for Hemophilia A. This decision means Sangamo will regain full rights to the program, but the market reaction has been negative, with the stock down sharply. The news has sparked discussions on
Sangamo Therapeutics is facing a significant setback after Pfizer decided to terminate their collaboration on the development of the hemophilia A gene therapy, giroctocogene fitelparvovec. This unexpected move by Pfizer, which had previously indicated plans to submit regulatory applications for the therapy in early 2025, has left Sangamo scrambling to regain full rights and explore new avenues for commercia
Sangamo Therapeutics, Inc. is experiencing a significant decline in its stock price after Pfizer announced it would return the development and commercialization rights for the hemophilia A gene therapy candidate, giroctocogene fitelparvovec, to Sangamo. This decision marks a major setback for Sangamo, which had been relying on the partnership with Pfizer to advance the therapy. The collaboration, initially
Sangamo Therapeutics (SGMO) experienced a significant decline today, closing at $2.34, down 8.59% from the previous close of $2.56. The stock opened at $2.49 and reached a high of $2.50 before declining to a low of $2.32. The trading volume was 4,470,589 shares, which is 51.93% of the average volume. The decline continued after hours, with the stock plummeting 34.62% to $1.53. The primary driver of today's
Sangamo Therapeutics, Inc. is facing a significant decline in after-hours trading, which appears to be linked to the company's recent announcement regarding its collaboration with Pfizer. Sangamo disclosed that it will regain the rights to giroctocogene fitelparvovec, a gene therapy for hemophilia A, from Pfizer. This development may have raised concerns among investors about the future prospects of the the
Sangamo Therapeutics, Inc. is experiencing a downturn today, potentially influenced by recent developments in the biopharmaceutical sector. Notably, Sangamo announced a significant licensing deal with Astellas Pharma Inc., securing $20 million upfront and the potential for up to $1.3 billion in milestone payments. This agreement, which spans five potential disease targets for gene therapies, was disclosed o
Sangamo Therapeutics (SGMO) experienced a decline today, closing at $2.39, down 3.24% from the previous close of $2.47. The stock opened at $2.34, reached a high of $2.59, and a low of $2.34, with trading volume at 5,852,188 shares, which is 69.99% of its average volume. Despite the recent positive news of a licensing agreement with Astellas Pharma, which includes a $20 million upfront payment and potential